Karyopharm Therapeutics (KPTI) Competitors $0.64 -0.01 (-2.25%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KPTI vs. SLRN, KMDA, TRVI, ETON, CGC, AQST, TNGX, SAGE, JSPR, and VALNShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Acelyrin (SLRN), Kamada (KMDA), Trevi Therapeutics (TRVI), Eton Pharmaceuticals (ETON), Canopy Growth (CGC), Aquestive Therapeutics (AQST), Tango Therapeutics (TNGX), Sage Therapeutics (SAGE), Jasper Therapeutics (JSPR), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Acelyrin Kamada Trevi Therapeutics Eton Pharmaceuticals Canopy Growth Aquestive Therapeutics Tango Therapeutics Sage Therapeutics Jasper Therapeutics Valneva Karyopharm Therapeutics (NASDAQ:KPTI) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, community ranking, earnings, profitability and media sentiment. Which has more volatility and risk, KPTI or SLRN? Karyopharm Therapeutics has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Is KPTI or SLRN more profitable? Acelyrin has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -58.93%. Karyopharm Therapeutics' return on equity of 0.00% beat Acelyrin's return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-58.93% N/A -41.25% Acelyrin N/A -44.12%-39.02% Does the media refer more to KPTI or SLRN? In the previous week, Acelyrin had 3 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 3 mentions for Acelyrin and 0 mentions for Karyopharm Therapeutics. Acelyrin's average media sentiment score of 0.58 beat Karyopharm Therapeutics' score of 0.00 indicating that Acelyrin is being referred to more favorably in the news media. Company Overall Sentiment Karyopharm Therapeutics Neutral Acelyrin Positive Which has higher earnings and valuation, KPTI or SLRN? Karyopharm Therapeutics has higher revenue and earnings than Acelyrin. Acelyrin is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$148.44M0.54-$143.10M-$1.14-0.56AcelyrinN/AN/A-$381.64M-$2.46-1.28 Does the MarketBeat Community prefer KPTI or SLRN? Karyopharm Therapeutics received 519 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 72.20% of users gave Karyopharm Therapeutics an outperform vote while only 59.26% of users gave Acelyrin an outperform vote. CompanyUnderperformOutperformKaryopharm TherapeuticsOutperform Votes53572.20% Underperform Votes20627.80% AcelyrinOutperform Votes1659.26% Underperform Votes1140.74% Do institutionals and insiders hold more shares of KPTI or SLRN? 66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 87.3% of Acelyrin shares are held by institutional investors. 4.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 13.6% of Acelyrin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend KPTI or SLRN? Karyopharm Therapeutics presently has a consensus price target of $5.00, indicating a potential upside of 687.40%. Acelyrin has a consensus price target of $11.75, indicating a potential upside of 273.02%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Acelyrin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Acelyrin 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryKaryopharm Therapeutics beats Acelyrin on 10 of the 17 factors compared between the two stocks. Ad Porter & CompanyAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.13M$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.90%4.21%P/E Ratio-0.5610.5090.8717.14Price / Sales0.54195.381,112.67116.85Price / CashN/A57.1642.1437.88Price / Book-0.535.104.784.78Net Income-$143.10M$151.51M$119.77M$225.60M7 Day Performance-9.29%-2.12%-1.87%-1.23%1 Month Performance-17.43%-3.11%11.46%3.07%1 Year Performance-16.51%11.52%30.49%16.48% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.8062 of 5 stars$0.64-2.2%$5.00+687.4%-16.2%$80.13M$148.44M-0.56380SLRNAcelyrin2.5887 of 5 stars$3.42+5.9%$11.75+243.6%-55.8%$343.13MN/A-1.31135KMDAKamada3.8898 of 5 stars$5.84-0.5%$14.50+148.3%-1.2%$335.68M$158.38M20.96360Positive NewsTRVITrevi Therapeutics3.0381 of 5 stars$4.34+4.1%$9.31+114.6%+214.0%$333.62MN/A-10.2020Gap DownHigh Trading VolumeETONEton Pharmaceuticals2.139 of 5 stars$12.91+4.5%$15.00+16.2%+176.9%$333.59M$31.64M-56.1420CGCCanopy Growth2.4388 of 5 stars$3.05-1.9%$3.50+14.8%-41.0%$332.27M$220.27M-0.631,029Analyst RevisionNews CoverageAQSTAquestive Therapeutics1.5038 of 5 stars$3.61flat$9.80+171.5%+95.2%$329.16M$50.58M-8.02160Analyst ForecastAnalyst RevisionNews CoveragePositive NewsTNGXTango Therapeutics1.8423 of 5 stars$3.06flat$13.14+329.5%-68.5%$328.70M$43.38M-2.5990News CoverageSAGESage Therapeutics4.1448 of 5 stars$5.22-3.2%$11.53+120.9%-73.1%$319.31M$86.46M-0.97690JSPRJasper Therapeutics2.3333 of 5 stars$21.00+1.9%$73.38+249.4%+290.1%$315.02MN/A-4.3520Positive NewsVALNValneva2.1578 of 5 stars$3.84-2.3%$18.50+381.8%-62.2%$312M$165.52M-30.23700News CoverageHigh Trading Volume Related Companies and Tools Related Companies Acelyrin Competitors Kamada Competitors Trevi Therapeutics Competitors Eton Pharmaceuticals Competitors Canopy Growth Competitors Aquestive Therapeutics Competitors Tango Therapeutics Competitors Sage Therapeutics Competitors Jasper Therapeutics Competitors Valneva Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KPTI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
